Published in Hepatitis Weekly, December 15th, 1997
Nonresponders, however, will need an alternative therapy or IFN-(alpha) combined with other treatment to obtain a sustained response.
A majority of hepatitis C patients do not maintain a sustained response to IFN therapy. To determine if retreatment of transient or nonresponders with recombinant IFN-(alpha) alone was effective, Liliana Chemello of the University of Padova and colleagues treated 92 such chronic hepatitis C virus (HCV) patients with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.